

1 The composition and function of *Enterococcus faecalis* membrane 2 vesicles

3 Irina Afonina^{1,2,3}, Brenda Tien^{1,2}, Zeus Nair^{1,4}, Artur Matysik^{1,2}, Ling Ning Lam^{1,2},
4 Mark Veleba^{1,2}, Augustine Koh^{1,2}, Rafi Rashid^{1,5}, Amaury Cazenave-Gassiot^{6,7},
5 Marcus Wenk^{6,7,8}, Sun Nyunt Wai⁹, Kimberly A. Kline^{1,2}

6 ¹Singapore Centre for Environmental Life Science Engineering, Nanyang Technological University, 60
7 Nanyang Drive, Singapore 637551

8 ²School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore
9 637551

10 ³Singapore–MIT Alliance for Research and Technology, Antimicrobial Drug Resistance
11 Interdisciplinary Research Group, Singapore 138602

12 ⁴Interdisciplinary Graduate School, Nanyang Technological University, Singapore

13 ⁵Graduate School for Integrative Sciences & Engineering, National University of Singapore, Singapore

14 ⁶Singapore Lipidomics Incubator, National University of Singapore, Singapore

15 ⁷Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore,
16 Singapore

17 ⁸Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore

18 ⁹Umeå Centre for Microbial Research (UCMR), Department of Molecular Biology, Umeå University,
19 90187 Umeå, Sweden

20 Abstract

21 Membrane vesicles (MVs) contribute to various biological processes in bacteria,
22 including virulence factor delivery, host immune evasion, and cross-species
23 communication. MVs are frequently being discharged from the surface of both Gram-
24 negative and Gram-positive bacteria during growth. In some Gram-positive bacteria,
25 genes affecting MV biogenesis have been identified, but the mechanism of MV
26 formation is unknown. In *Enterococcus faecalis*, a causative agent of life-threatening
27 bacteraemia and endocarditis, neither mechanisms of MV formation nor their role in
28 virulence has been examined. Since MVs of many bacterial species are implicated in
29 host-pathogen interactions, biofilm formation, horizontal gene transfer, and virulence
30 factor secretion in other species, we sought to identify, describe, and functionally
31 characterize MVs from *E. faecalis*. Here we show that *E. faecalis* releases MVs that
32 possess unique lipid and protein profiles, distinct from the intact cell membrane, and
33 are enriched in lipoproteins. MVs of *E. faecalis* are specifically enriched in
34 unsaturated lipids that might provide membrane flexibility to enable MV formation,
35 providing the first insights into the mechanism of MV formation in this Gram-positive
36 organism.

37 Introduction

38 Membrane vesicles (MVs) are widely produced by Gram-negative and Gram-positive
39 bacteria. While MVs confer many similar functions to Gram-positive and Gram-
40 negative bacteria, including virulence factor delivery and host immune modulation,
41 the mechanism of MV formation differs due to intrinsic differences in the structure of
42 the cell wall [1-5]. MVs are well-studied in Gram-negative bacteria where they are
43 derived from the outer membrane and are produced under the normal growth and
44 stress conditions [6-9]. Since Gram-positive bacteria lack an outer membrane and
45 have a thicker peptidoglycan which could impact MV formation or release, MVs in
46 Gram-positive bacteria were largely neglected until the first report in 2009
47 characterizing MVs from *Staphylococcus aureus* [10]. Since then, MVs have been
48 reported in numerous Gram-positive bacteria including *Bacillus subtilis*,
49 *Streptococcus pyogenes*, *Streptococcus mutans*, *Listeria monocytogenes*,
50 *Enterococcus faecium*, but not in *Enterococcus faecalis* [3, 10-14]. While several
51 mechanisms for outer membrane vesicle (OMV) formation in Gram-negative bacteria
52 have been proposed, the mechanism of MV formation in Gram-positive bacteria is
53 largely unknown [15]. In Gram-positive bacteria, MV biogenesis can be regulated
54 genetically. In *L. monocytogenes*, RNA polymerase sigma factor σ_B , a general
55 stress transcription factor that activates stress response genes and *ftsZ*, contributes
56 to MV formation with significantly reduced vesiculation in a $\Delta sigB$ mutant [14].
57 Similarly, MV biogenesis in *M. tuberculosis* is affected by VirA (vesiculogenesis and
58 immune response regulator) and vesiculation increases in a VirA deficient mutant
59 [16]. In *S. pyogenes*, the two-component system CovRS negatively impacts
60 vesiculation [17].

61 *E. faecalis* is an opportunistic pathogen that can cause urinary tract infections (UTI),
62 catheter associated urinary tract infections (CAUTI), wound infection, and life-
63 threatening bacteraemia and endocarditis [18-20]. Infections by this opportunistic
64 pathogen can be difficult to treat due to their propensity to form biofilms, as well as
65 their frequent and multiple antibiotic resistances [21]. *E. faecalis* and *E. faecium* both
66 cause disease in humans, but *E. faecalis* is more frequently isolated from clinical
67 specimens [20]. Understanding the mechanism of vesiculation in *E. faecalis* and the
68 role MVs play in virulence, may improve strategies to treat enterococcal infections.

69 **Methods**

70 **Bacterial strains and growth conditions**

71 *Enterococcus faecalis* OG1RF and *Escherichia coli* DH5 α with or without the plasmid
72 pGCP123 [22] were used in this study. *E. faecalis* strains were grown statically in
73 brain heart infusion media (BHI; BD Difco, USA) or on BHI agar (BHI supplemented
74 with 1.5% agarose (1st BASE, Singapore)) at 37°C. *E. coli* was grown in Luria-
75 Bertani Broth (Miller) (LB; BD, Difco, USA) at 37°C, 200 rpm shaking. For biofilm
76 assays, tryptone soy broth (Oxoid, UK) supplemented with 10 mM glucose (TSBG)
77 was used. Kanamycin (kan) was used in the following concentrations where
78 appropriate: 50 μ g/mL (*E. coli*), 500 μ g/mL (*E. faecalis*), unless otherwise noted.

79 **Genetic manipulations**

80 To construct the in-frame deletion of pp2 (OG1RF 11046-11063), regions
81 approximately 1Kb upstream and downstream of the genes were amplified from
82 OG1RF using primer pairs pp2.infu.1F/R and pp2.infu.2F/R for upstream and
83 downstream regions, respectively (**Table S1**). These products were sewn together
84 and amplified using pp2.infu.1F / pp2.infu.2R. The temperature sensitive plasmid
85 pGCP213 was amplified using the pGCPinphuF/R primer pair. The pp2.infuF/R PCR
86 product of approximately 2Kb was then cloned into the pGCP213 fragment using the
87 In-Fusion HD Cloning Plus System (Takara Bio Inc, Shimogyō-ku, Kyoto) to
88 generate the temperature sensitive deletion plasmid pGCPpp2.

89 Deletion constructs were then transformed into OG1RF by electroporation and the
90 transformants were selected at 30°C on agar plates with kan. Chromosomal
91 integrants were selected by growth at 42°C on the agar plate in the presence of kan.
92 Selection for excision of the integrated plasmid by homologous recombination was
93 accomplished by growing the bacteria at 30°C in the absence of kan in the broth.
94 Loss of the pp2 locus in kanamycin-sensitive bacteria was demonstrated by PCR
95 using primer pair infu_check_pp2F/R

96 **Membrane vesicle isolation**

97 A single *E. faecalis* colony was inoculated into 100 mL of BHI broth and grown
98 overnight. The resulting overnight culture was diluted 1:10 with warm fresh BHI and
99 grown for 2 hours. Cells were harvested using a Beckman centrifuge and JA 12.650

100 rotor at 4000 x g for 15 min at 4°C. Supernatants were filtered through a 0.45 µm
101 vacuum filter and concentrated to 70 mL using a VIVAFLOW 100,000 MWCO
102 Hydrosart (Sartorius, Germany). Concentrated supernatants were then subjected to
103 ultracentrifugation at 160,000 x g for 2 hours at 4°C using a Beckman Ti 45 rotor
104 (Beckman, Germany). Supernatants were completely removed and the pellet
105 containing the crude MV fraction was resuspended in 400 µL of chilled PBS. MVs
106 were further purified using density gradient centrifugation as previously described
107 [23]. Briefly, 400 µL of PBS containing crude MVs was layered over an OptiPrep
108 density gradient in a 4.2 mL tube in the following order from bottom to top: 400 µL
109 (45% OptiPrep), 500 µL (35% OptiPrep), 600 µL (30% OptiPrep), 600 µL (25%
110 OptiPrep), 600 µL (20% OptiPrep), 500 µL (15% OptiPrep), 600 µL (10% OptiPrep).
111 The 4.2 mL tubes were centrifuged in a SW60 Ti rotor (Beckman Coulter, USA) for 3
112 hours at 160,000 x g at 4°C. After centrifugation, 200 µL OptiPrep gradient aliquots
113 were removed from the top and transferred into 21 Eppendorf tubes (21 fractions in
114 total). Collected fractions were subjected to SDS-PAGE and silver staining. Fractions
115 13-16 containing MVs were combined and used within two days or stored at – 80°C
116 until further analysis. For Nanosight, proteomics, and lipidomic analyses, samples
117 were further purified from OptiPrep by ultracentrifugation at 160,000 x g for 2 hours
118 and the pellet was resuspended in 50 µL of PBS.

119 **Transmission electron microscopy (TEM) analysis**

120 For negative staining, 4 µL of sample was deposited onto glow-discharged carbon-
121 coated copper grids (NTU, Singapore). After 1 min, the sample was blotted with a
122 filter paper and 4 µL of 1% uranyl acetate was added onto the grid. After 1 min,
123 excess uranyl acetate was removed. Samples were visualized using a T12 120kV
124 TEM (Fei, USA).

125 **Live imaging**

126 Late-log *E. faecalis* sub-culture in BHI was washed in PBS, stained with Nile Red
127 (10µg/mL) for 10 mins at room temperature, washed again in PBS, spotted on 1mm
128 thick BHI agar (1.5%) pad prepared on a glass slide and mounted with coverslip
129 (glass-agar-glass). Sample was then imaged using Zeiss Axio Observer 7 widefield
130 epifluorescence microscope, equipped with 100x/1.4NA PlanApochromat oil-
131 immersion objective and Hamamatsu Orca Flash 4.0 detector. Images were acquired

132 with 2 seconds interval with minimal excitation light intensity but sufficient for
133 imaging, to minimize photobleaching and phototoxicity effects. Images were then
134 processed using ImageJ/FIJI.

135 **Nanosight analysis**

136 Purified MV samples were analysed with a NanoSight NS300 (Malvern Instruments,
137 UK) according to the manufacturer's protocol. Briefly, the system was first washed 3
138 times with 1 mL sterile water. Next, the sample was diluted 1:10 in 1X PBS and
139 loaded into the chamber with a sterile syringe to ensure no bubbles were trapped in
140 the installed tubing. All samples were captured under the same settings and
141 concentration and size were calculated automatically by NanoSight NS300 Control
142 Software (Malvern Instruments, UK).

143 **MV plasmid transfer assay**

144 250 μ L of purified MV sample was added to 10^4 CFU/mL of recipient OG1RF or
145 DH5 α in 250 μ L of 2X BHI (for *E. faecalis* OG1RF) or 2X LB (for *E. coli* DH5 α) broth.
146 Two hours after incubation, 100 μ L of recipient *E. faecalis* or *E. coli* DH5 α was plated
147 on BHI agar (kan 1000 μ g/mL) for *E. faecalis* or LB agar *E. coli* (kan 50 μ g/mL) in
148 duplicates. The remaining volume of recipient *E. faecalis* OG1RF or *E. coli* DH5 α
149 was serially diluted plated on plain BHI/ LB agar, incubated overnight for CFU
150 enumeration.

151 **DNA quantification**

152 DNA concentration in MV samples before and after heating at 95°C for 10 mins was
153 measured by Qubit (Qubit[®] 2.0 Fluorometer, Invitrogen™, Thermo Fisher Scientific)
154 as per user manufacturer's instructions.

155 **DNase treatment**

156 Five μ L of crude or purified MV sample was treated with 1 μ L DNase in a 50 μ L
157 reaction volume for 30 min at 37°C. 10 ng of purified pGCP123 was added to control
158 samples. Where indicated, DNase was inactivated at 98°C for 10 min prior to
159 addition of the sample and PCR reaction using primers to amplify pGCP123 plasmid:
160 M13 Forward (5'-GTAAAACGACGGCCAGTG-3')/ Reverse (5'-
161 CAGGAAACAGCTATGAC-3').

162 **Cell culture and NF- κ B reporter assay**

163 RAW-Blue cells derived from RAW 264.7 macrophages (Invivogen), containing a
164 plasmid encoding a secreted embryonic alkaline phosphatase (SEAP) reporter under
165 transcriptional control of an NF- κ B-inducible promoter, were cultivated in Dulbecco
166 Modified Eagle medium containing 4500 mg/L high glucose (1X) with 4.0 nM L-
167 glutamine without sodium pyruvate (Gibco), and supplemented with 10% fetal bovine
168 serum (FBS) (Gibco) supplemented with 200 μ g/mL Zeocin at 37°C in 5% CO₂.

169 RAW-Blue cells were seeded in a 96 well plate at 100,000 cells/well in 200 μ L of
170 antibiotic-free cell culture media. Following overnight incubation, the cells were
171 washed once with PBS and fresh media was added. Cells were stimulated using
172 LPS purified from *E. coli* O111:B4 (Sigma Aldrich) (100 ng/mL) as a positive control,
173 or cell culture media alone or OptiPrep alone as negative controls. MVs purified in
174 OptiPrep (1000 particles/macrophage) were added to RAW-Blue cells and incubated
175 for 6 hours with or without simultaneous LPS stimulation. Post-infection, 20 μ L of
176 supernatant was added to 180 μ L of QUANTI-Blue reagent (Invivogen) and
177 incubated overnight at 37°C. SEAP levels were determined at 640 nm using a
178 TECAN M200 microplate reader.

179 **Protein content analysis**

180 Purified MV samples or mid-log phase intact bacterial cells, washed in PBS and
181 incubated in lysis buffer with 1 mg/mL lysozyme for 1 hour at 37°C, were boiled in 1X
182 NuPAGE[®] LDS sample buffer (Invitrogen, USA) and 0.1 M dithiothreitol (DTT) at
183 95°C for 10 min. Samples were run on 10% NuPAGE[®] Bis-Tris mini gel
184 (ThermoFisher Scientific, USA) in 1x MOPS SDS running buffer in XCellSureLock[®]
185 Mini-Cell for 10 min at 150 V. Gel lanes containing silver stained proteins were cut
186 out and sent to the Harvard Medical School Taplin Mass Spectrometry facility for
187 mass spectrometry (MS) analysis (Harvard, USA). From the list of identified proteins
188 within each sample, proteins containing fewer than 3 unique peptides were excluded
189 from the analysis. All the other proteins were assigned an abundance score (A*)
190 based on the number of unique peptides per protein divided by the total number of
191 unique peptides. We averaged A* within triplicates and sorted proteins in descending
192 order based on the A*. The most abundant proteins are the top 10 proteins based on
193 the A*, the enriched proteins were identified as A* of the protein within MV sample

194 divided by A^* of the same protein within whole cell lysate fraction. If the protein was
195 not present within the whole cell lysate fraction, A^* was defined as 0.06, the lowest
196 abundance within all proteins in WCL, when calculating enrichment.

197 **Lipid content analysis**

198 Lipids were extracted from lyophilised membrane vesicles or whole cell pellets, using
199 a modified Bligh & Dyer method as previously described [24, 25]. Prior to extraction,
200 samples were spiked with known amounts of internal standards for
201 phosphatidylglycerol (PG) and lysyl-phosphatidylglycerol (Lys-PG) or external
202 calibration standard, monoglucosyl-diacylglycerol (MGDAG 34:1) (Avanti polar lipids,
203 Alabaster, AL, USA) and were run alongside the samples (**Table S2**).

204 PG and L-PG in WCL and MVs were quantified by LC-MS/MS using multiple reaction
205 monitoring (MRM) that we previously established [24]. An Agilent 6490 or 6495A
206 QqQ mass spectrometer connected to a 1290 series chromatographic system was
207 used together with electrospray ionization (ESI) for lipid ionisation. Each lipid
208 molecular species was analyzed using a targeted MRM approach containing
209 transitions for known precursor/product mass-to-charge ratio (m_1/m_3). Signal
210 intensities were normalized to the spiked internal standards (PG 14:0 and L-PG
211 16:0) to obtain relative measurements, as described previously (13). Due to an
212 absence of suitable internal standards, semi-quantitative analysis of diglucosyl-
213 diacylglycerol (DGDAG) was carried out instead. Lipid extraction was performed
214 without spiking of internal standards and DGDAG lipid species were analysed by LC-
215 MS/MS using MRMs using monoglucosyl-diacylglycerol (MGDAG) 34:1 as a
216 surrogate standard (**Table S2**) for external calibration curves. Measurements of
217 MGDAG 34:1 dilution, from 0.2 ng/mL to 1000 ng/mL were used to construct external
218 calibration curves to estimate the levels of DGDAG. The MRM transitions for
219 DGDAG molecular species and MGDAG 34:1 are listed in **Table S3**. All lipid species
220 abundances were expressed as a percentage of their respective lipid class.

221 **Statistical Analysis**

222 Statistical analyses were performed using GraphPad Prism software (Version 6.05
223 for Windows, California, United States). All experiments were performed at least in
224 three biological replicates and the mean value was calculated. All graphs indicate
225 standard deviation from independent experiments. Statistical analysis was performed

226 by unpaired t-test using GraphPad (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; **** $p < 0.0001$,
227 ns: $p > 0.05$). SEAP assays were analyzed using one-way ANOVA with Tukey's
228 multiple comparison. *P*-values less than 0.05 were deemed significant.

229 **Results**

230 ***E. faecalis* produces MVs with a size range of 50-400nm**

231 To determine whether *E. faecalis* produces MVs, we used methods previously
232 described for the isolation of MVs from Gram-positive bacteria [10]. We collected
233 cell-free supernatants of late-log phase cultures and performed ultracentrifugation to
234 obtain a crude pellet. We then separated the crude pellet by OptiPrep gradient
235 centrifugation, from which we collected 22 fractions followed by SDS PAGE and
236 silver stain (**Figure 1A**). We observed a denser staining pattern with altered protein
237 abundances in fractions 13-16, at approximately 25% OptiPrep, a similar density at
238 which MVs were found for *S. aureus* and *E. coli* [10, 26, 27].

239 To determine whether fractions 13-16 contained MVs, we performed transmission
240 electron microscopy (TEM) on fraction 15 (MV fraction) as well as 3 other fractions
241 chosen to represent the crude sample after the centrifugation (fraction 3), and
242 fractions before (fraction 7) and after (fraction 21) those predicted to contain MVs in
243 the gradient. We observed spherical, double membrane particles resembling MVs
244 described in other Gram-positive species in fraction 15, but not in the other three
245 fractions (**Figure 1B**) [2, 12]. To further characterize MVs observed in fraction 15, we
246 combined fractions 13-16 in order to increase our sample mass, and measured the
247 size and concentration of MVs by dynamic light scattering using a Nanosight NS300
248 instrument. MVs varied in size with a diameter ranging from 40-400 nm (**Figure S1**),
249 similar to that reported for other Gram-positive bacteria [3, 13, 28]. To visualize MV
250 formation in situ, we imaged live *E. faecalis* mounted on agar pads and stained with
251 Nile Red in late-log phase. Acquired time series revealed increasing number of small
252 (resolution limited) vesicles that appear to detach from the cell body, and continue to
253 diffuse in close bacterial proximity, most likely trapped in a confined volume around
254 the cell between agar and glass slide (**Figure 1C, Supplementary video 1A, 1B**).

255 ***E. faecalis* MVs are enriched in unsaturated lipids**

256 The bacterial membrane is non-homogenous, containing distinct microdomains
257 associated with functions including bacterial secretion and virulence, and which may
258 serve as targets for antimicrobials [29, 30]. Since the *E. faecalis* membrane also
259 contains lipid microdomains where secretion and virulence factor assembly functions
260 are enriched [30-32] and since MVs are associated with distinct lipid repertoires in
261 some bacteria [17], we considered the possibility that *E. faecalis* MVs are also
262 released from specific lipid microdomains on the bacterial membrane. To address
263 this question and ask whether *E. faecalis* MVs are composed of distinct lipid subsets,
264 we analysed the lipidomes of purified MVs (25-30% of OptiPrep density) to entire
265 membrane of late log phase bacterial cells. We analysed the lipid composition from
266 five independent biological samples by liquid chromatography tandem mass
267 spectrometry (LC-MS) using multiple reaction monitoring (MRM) methods previously
268 established for (PG) and lysyl-phosphatidylglycerol (Lys-PG), as well as newly
269 developed MRMs for diglucosyl-diacylglycerol (DGDAG) [24].

270 Within the PG species, which are the predominant lipid in the *E. faecalis* lipid
271 membrane [24], we observed a significant increase in the overall abundance of
272 polyunsaturated lipids (PG 32:2; PG 34:2), and reduction in monounsaturated and
273 saturated lipids (PG 34:0, PG 35:0, PG 32:1, PG 34:1, PG 36:1) in MV samples as
274 compared to whole cell lysates (WCL) (**Figure 2A**). For the less abundant DGDAG
275 lipid species, the trend is similar in that we observe an increase in overall
276 polyunsaturated species (**Figure 2B**). While we observed differences in individual
277 species of Lys-PG (increased 34:1 and 33:2 in MVs, decreased 34:2 in MVs), the
278 overall levels of saturation for Lys-PG were similar between MV and WCL. (**Figure**
279 **2C**).

280 ***E. faecalis* MVs possess a unique proteome**

281 To further characterize the properties of *E. faecalis* MVs, we performed proteomic
282 analysis on OptiPrep-purified MVs and from late-log phase whole cells using
283 LC/MS/MS [33]. Proteins for which three or more unique peptides were identified
284 were considered in the analysis. In total, we identified 225 proteins from MV samples
285 and 397 proteins from whole cell lysates, and sorted the proteins based on their

286 calculated average abundance score (**Tables S4** and **S5**). Abundance was
287 calculated as the number of unique peptides for a given protein divided by the total
288 number of peptides within each sample, and the average abundance for each protein
289 in the three biological replicates is reported. In addition, enrichment of each protein
290 was calculated as the average abundance in the MV fraction divided by the average
291 abundance of the same protein in the whole cell fraction. Next, we sorted the 15
292 most abundant and 15 enriched proteins in the MVs, and established 10 “signature”
293 MV proteins that were both most abundant and most enriched in MV fractions
294 relative to whole cells (**Figure 3, Table 1**). Within those are IreK (OG1RF_12384), a
295 eukaryote-like Ser/Thr kinase and phosphatase; penicillin binding proteins Pbp1A,
296 Pbp1B and PenA; a S1 family extracellular protease OG1RF_12235; lipoprotein
297 (OG1RF_12508); CnaB and 2 ABC superfamily ATP binding cassette transporters
298 (OG1RF_10124 and OG1RF_12508).

299 In addition to a phage tail protein OG1RF_11061 that was found among the 15 most
300 enriched proteins, we detected an additional 4 phage proteins encoded at a
301 previously described phage02 locus that are only present in MV fraction and are not
302 found in a whole cell lysate (**Table S4**). The phage02-encoding operon (OG1RF
303 11046-11063) is a part of the *E. faecalis* core genome and considered cryptic
304 because it lacks crucial genes for DNA packaging and excision [34]. However, we
305 observed phage tail-like structures in the purified MV fraction by TEM (**Figure 4A**). In
306 *Pseudomonas aeruginosa* MVs can be formed as a result of explosive cell lysis
307 mediated by cell-wall modifying phage endolysins that degrade the bacterial
308 membrane to burst the bacterial cell, resulting in MV formation and spontaneous
309 membrane reannealing [7]. We hypothesized that phage tails could be assembled
310 inside *E. faecalis* cells and released through explosive cell lysis, concurrently
311 contributing to MV formation. We performed TEM on mid-log phase bacteria and
312 observed MVs closely associated with the bacterial surface (**Figure 4B**), similar to
313 bacteria-associated MVs observed in *P. aeruginosa* upon phage-mediated cell lysis
314 [7]. To test whether phage-mediated explosive cell lysis occurred in *E. faecalis*, we
315 first generated a strain in which the entire phage02 operon was deleted ($\Delta pp2$),
316 including the predicted phage structural proteins, holin, and endolysin genes. We
317 performed TEM on MVs isolated from WT and $\Delta pp2$ and confirmed absence of the
318 phage tails in the $\Delta pp2$ phage deletion mutant (data not shown).

319

320 To determine whether the phage02-encoded factors, such as an endolysin,
321 contributed to cell lysis and MV formation, we quantified MVs from WT and $\Delta pp2$, but
322 observed no difference in MV numbers between the two strains (**Figure 4C**). Since
323 phage02 is the only predicted phage element in the OG1RF genome, these findings
324 suggested that a phage-mediated mechanism, such explosive cell lysis, does not
325 significantly contribute to *E. faecalis* MV formation.

326 ***E. faecalis* MVs do not mediate intra-species or cross-genera** 327 **horizontal gene transfer *in vitro***

328 OMVs from Gram-negative bacteria may contain DNA from chromosomal, plasmid,
329 or viral origin [35]. Plasmid and chromosomal DNA carrying antibiotic resistance
330 genes can be transferred via OMVs to cells of the same or different genera to confer
331 antibiotic resistance in the recipient [36, 37]. Among Gram-positive bacteria,
332 *Clostridium perfringens* and *S. mutants* pack chromosomal DNA in MVs [11, 38]. A
333 single report on MV-mediated horizontal gene transfer (HGT) in Gram-positive
334 bacteria demonstrated the ability of a MV-containing fraction from WT *Ruminococcus*
335 *sp.* strain YE71 to transform and permanently restore cellulose-degrading activity to
336 a Cel⁻ mutant that was otherwise unable to degrade cellulose [39]. We tested if *E.*
337 *faecalis* can pack plasmids inside MVs for HGT to another *E. faecalis* strain or to
338 another species. We first isolated MVs from plasmid-carrying OG1RF pGCP123 [22],
339 a 3045 bp, non-conjugative plasmid that can stably replicate in both Gram-positive
340 and Gram-negative bacteria and which encodes kanamycin-resistance.

341 To first determine if *E. faecalis* MVs contain DNA, we quantified DNA from the intact
342 MV prep before and after the MV lysis. We observed a ~150% increase in DNA
343 concentration from lysed sample, compared to the intact MV, indicating that bacterial
344 DNA is present within MV lumen (**Figure 5A**). To determine if plasmid DNA is
345 present within the MV prep, we performed PCR with plasmid-specific primers on the
346 crude and purified MV fractions, using purified pGCP123 plasmid as a control. We
347 observed a plasmid-specific PCR product of 229 bp in the plasmid control and MV
348 sample from plasmid-carrying strains (**Figure 5B**) indicating that plasmid DNA is
349 present in both crude and purified MV fractions. In principle, plasmid DNA can be
350 either packed inside MVs or associated with the exterior of MVs (and therefore co-

351 purified with MVs). To address localization of pGCP123 with respect to *E. faecalis*
352 MVs, we exposed MVs to DNase in order to degrade any extracellular plasmid
353 (**Figure 5C**). To control for efficiency of DNase treatment, we used purified plasmid
354 and lysed MVs as controls. We observed a plasmid-specific PCR product only in
355 DNase untreated samples. To ensure that DNase was fully inactivated after
356 incubation with MVs, and didn't continue to digest plasmid DNA released from MVs
357 during the PCR reaction, we mixed purified MVs with the same amount of DNase
358 followed by immediate DNase inactivation by boiling at 98°C for 10 min. We
359 observed a plasmid-specific PCR product in the inactivated DNase sample
360 suggesting that DNase was fully inactivated before the PCR reaction. Hence, the
361 observed an increase in DNA concentration upon MV lysis (**Figure 5A**), indicates
362 that bacterial DNA is present within MVs. This MV resident DNA, however, likely
363 does not contain plasmids since we show that plasmid DNA is not present within MV
364 lumen, but instead co-purifies with MVs.

365 To determine if plasmids co-purified with MVs could mediate HGT, we exposed
366 purified MVs to plasmid free strains of *E. faecalis* and *E. coli* for 2 hours to allow for
367 plasmid transfer prior plating bacteria on selective plates containing kanamycin.
368 However, we detected no resistant colonies on the selective plates suggesting that
369 plasmid was not transferred to *E. coli* or *E. faecalis* by MVs under these
370 experimental conditions (**Figure 5D**).

371 **MVs modulate the NF- κ B response in macrophages**

372 Proteomic analysis identified 5 lipoproteins (OG1RF_11390, OG1RF_11130,
373 OG1RF_11506, OG1RF_12508, OG1RF_12509) enriched in MVs, similar to reports
374 of lipoprotein-rich MVs from *S. pyogenes* and *M. tuberculosis* [12, 16] (**Tables S3**
375 **and S4**). Mycobacteria-derived MVs bear 2 lipoproteins which are demonstrated
376 agonists of the Toll-like 2 receptor and that activate an inflammatory response in
377 mice. By contrast, MVs from *S. pyogenes* do not activate TLR2, indicating that the
378 immunogenic potential of MVs varies between species [12, 16, 40]. We have
379 previously shown that *E. faecalis* activates macrophages at low multiplicities of
380 infection (MOI) and is immunosuppressive to macrophages at high MOI [41]. To
381 determine whether *E. faecalis* MVs contribute to immune suppression or activation,

382 we tested the NF- κ B response of macrophages upon exposure to *E. faecalis* MVs.
383 We purified MVs using OptiPrep and added them to RAW-blue macrophages (1000
384 MVs/macrophage) with or without LPS to assess their ability to activate NF- κ B
385 signalling on their own, or suppress LPS-mediated activation. Purified
386 lipopolysaccharide (LPS) served as a positive control for maximal NF- κ B activation
387 and 25% OptiPrep media as a negative control. We also combined the first 10
388 fractions from the OptiPrep gradient after centrifugation to serve as a MV-free
389 concentrated supernatant for a secondary negative control. In this assay, we
390 observed that *E. faecalis* MVs activate NF- κ B signalling in macrophages (**Figure 6**).
391 Since we observed that the MV fraction from WT *E. faecalis* co-purified with
392 bacteriophage tails (**Figure 4**), and since fully assembled bacteriophages can be
393 immunomodulatory and suppress phagocytosis and LPS-induced phosphorylation of
394 NF- κ Bp65 [42-44], we next dissected whether phage tails contribute to MV-mediated
395 activation of NF- κ B in macrophages (**Figure 6**). We isolated MVs from $\Delta pp2$ lacking
396 the whole prophage operon and compared the NF- κ B response to the response
397 elicited by MVs from WT. We observed no statistical difference in NF- κ B reporter
398 activity of $\Delta pp2$ mutant (MVs only) compared to WT (MVs + phage tails), suggesting
399 that MVs alone are immunostimulatory and can induce NF- κ B signalling in
400 macrophages, regardless of the presence of co-purified phage tails (**Figure 6**).

401 Discussion

402 Vesicle shedding from bacteria is a common process in Gram-negative and Gram-
403 positive bacteria. Yet the mechanisms of MV formation and function, especially in
404 Gram-positive species are largely unknown. MVs of Gram-positive bacteria possess
405 unique proteomes, are immunogenic, and in some cases contribute to host cells
406 death by carrying toxins [2, 3, 40, 45]. In this study, we report that the opportunistic
407 pathogen *E. faecalis* strain OG1RF produces MVs ranging in size from 40-400nm.
408 *E. faecalis* MVs are enriched for a unique subset of proteins, unsaturated lipids, and
409 are capable of activating NF- κ B signalling in macrophages.

410 Several studies have compared the lipid profile of MVs to that of the complete
411 bacterial membrane. In Group A streptococcus, MVs are enriched in PG and
412 significantly reduced in CL while the saturation levels of fatty acids remained

413 unchanged [17]. In *Propionibacterium acnes*, MVs also possess a distinct lipid profile
414 with levels of triacylglycerol significantly lower compared to the cell membrane [46].
415 Both reports suggest that lipid composition and distribution in MVs can be very
416 different from that of the bacterial cell membrane, supporting the hypothesis that MV
417 formation is not a random process. In *E. faecalis*, we observed a significant increase
418 in the levels of unsaturated PG in MVs as compared to the whole cell membrane.
419 Unsaturated lipids enhance membrane fluidity and partition to ordered domains in
420 more fluid regions of the bilayer [46, 47]. In model membranes, more flexible
421 unsaturated lipids become concentrated in tubular regions pulled from a vesicle and
422 unsaturated lipids are sorted into pathways involving highly curved tubular
423 intermediates [48]. Therefore, *E. faecalis* microdomains with polyunsaturated PGs
424 might provide additional flexibility for vesicle formation.

425 In addition to a distinct lipid profile, *E. faecalis* MVs possess a unique proteome.
426 Among MV signature proteins are penicillin binding proteins, Pbp1A and Pbp1B,
427 which dynamically localize in the inner membrane in *E. coli* but are also enriched in
428 the septal divisome during cell division [49, 50]. In *Streptococcus pneumoniae*
429 division and are localized to the septum region [51] These observations are
430 consistent with a model in which *E. faecalis* MVs might be formed from the Pbp-
431 enriched septal region during cell division. Consistent with this hypothesis, within the
432 signature MV proteins, we detected the serine-threonine kinase IreK that monitors
433 cell wall integrity and mediates adaptive responses to cell wall-active antibiotics [52,
434 53]. An IreK homologue in *S. pneumoniae* – StkP - is localized at the division septum
435 via penicillin-binding protein and serine/threonine kinase associated (PASTA)
436 domains linked to un-crosslinked PG, the same unique domains that are present in
437 enterococcal IreK [54, 55]. The abundance of likely septum-localized proteins within
438 *E. faecalis* MVs suggests that MV formation is a spatiotemporally organized process,
439 and might be driven through IreK signalling at the septum. Moreover, by *in situ* live
440 imaging MVs appeared to be derived from the septal region, further supporting
441 septal vesiculation model.

442 Supplementary to MV release from septal polyunsaturated PG microdomains, it was
443 formally possible that *E. faecalis* MVs might be formed through explosive cell lysis
444 mediated by phage tail release, similar to MV formation during bacteriophage

445 release in *P. aeruginosa* [7]. Indeed, we observed that MVs co-purified with fully-
446 assembled phage tails encoded by a cryptic phage. While we didn't observe
447 significantly changed MV numbers between the WT and $\Delta pp2$ phage mutant, the
448 question of what function these phage tails might confer to *E. faecalis* now stands.
449 Moreover, in *P. aeruginosa*, a population of MVs were observed to be attached to
450 cells adjacent to those which underwent lysis, which would not be reflected in MV
451 quantification experiments. Therefore, we cannot yet rule out partial contribution of
452 explosive cell lysis to MV formation in *E. faecalis*.

453 Finally, we observed that lipoproteins are enriched in MVs, similar to MVs from *S.*
454 *pyogenes* and *M. tuberculosis* [12, 16]. Lipoproteins are potent inducers of the host
455 inflammatory responses through TLR2 receptors, and lipoprotein-rich MVs from *M.*
456 *tuberculosis* and *C. perfringens* activate macrophages, leading to the release
457 of inflammatory cytokines [28, 40, 56]. In *L. monocytogenes*, pheromone cAD1, the
458 homologue of pheromone cAD1 lipoprotein that is enriched in enterococcal MVs,
459 enhances bacterial escape from host cell vacuoles and bacterial virulence [57]. We
460 hypothesize that *E. faecalis* lipoprotein-enriched MVs may contribute to their ability
461 to promote NF- κ B activation in macrophages. In addition, it is possible that MV-
462 associated unmethylated prokaryotic DNA is recognized by TLR9 receptors on host
463 immune system cells leading to NF- κ B activation [58, 59]. Finally, bacterial lipids can
464 engage pattern recognition receptors on host cell membranes to control inflammation
465 and immunity by interacting with TLR2 and TLR4 receptors [60, 61]. Whether lipids
466 present within enterococcal MVs play a role in immune modulation remains unclear.
467 The precise roles for enterococcal MVs during infection, whether they confer benefits
468 via immune modulation or promoting bacterial growth and survival, are the subject of
469 ongoing investigation.

470 In summary, we identified that *E. faecalis* MVs are composed of distinct protein and
471 lipid profiles, suggesting they may arise via a regulated MV biogenesis process from
472 the septum, where the cell-wall is thinnest and which may be enriched with more
473 flexible polyunsaturated microdomains. Functionally, *E. faecalis* MVs activate NF- κ B
474 signalling in macrophages, possibly due to their abundance of immunogenic
475 lipoproteins. Future work on mechanisms of MV formation and comparing the
476 function of MVs from both commensal and pathogenic *E. faecalis* strains will

477 enhance our understanding in enterococcal pathogenesis and host-pathogen
478 interactions.

479 **Acknowledgements**

480 This work was supported by the National Research Foundation and Ministry of
481 Education Singapore under its Research Centre of Excellence Programme, as well
482 as the National Research Foundation under its Singapore NRF Fellowship
483 programme (NRF- NRFF2011-11). This work was also supported by a Tier 1 grant
484 sponsored by the Singapore Ministry of Education (MOE2017-T1-001-269).

485 We are grateful to Jenny Dale and Gary Dunny for supplying us with *E. faecalis*
486 OG1RF transposon mutants used in this study. We also thankful to the
487 Taplin Biological Mass Spectrometry Facility and Ross Tomaino for the MS analysis.
488 The TEM work was undertaken at the NTU Institute of Structural Biology Cryo-EM
489 lab in Nanyang Technological University, Singapore. We thank Andrew Wong for the
490 assistance in sample prep and imaging. We also thank Annika Sjöström and Monica
491 Persson from Umea University, Sweden for advice on MV isolation and atomic force
492 microscopy.

493 **Table 1. Function and rank position of the top 15 most abundant and enriched**
 494 **proteins identified in MVs by MS.** Where n/p – not present in WCL within 397
 495 identified proteins; in bold are the most abundant and the most enriched “signature”
 496 proteins (description to **Figure 3**).

Protein	Position in MVs (of 225)	Position in WCL (of 397)	Function
Aad	1	8	Aldehyde-alcohol dehydrogenase
GroL	2	15	Chaperonin
OG1RF_12384	3	168	Non-specific serine/threonine protein kinase
Pbp1A	4	n/p	Penicillin binding proteins 1A
CnaB	5	n/p	Cna protein B-type domain protein
OG1RF_10124	6	151	ABC superfamily ATP binding cassette transporter, binding protein
OG1RF_12508	7	n/p	Thiamine biosynthesis lipoprotein
OG1RF_12203	8	155	ABC superfamily ATP binding cassette transporter, substrate-binding protein
OG1RF_10125	9	67	ABC superfamily ATP binding cassette transporter, binding protein
PenA	10	n/p	Penicillin-binding protein 2 gene
OppA	11	33	Oligopeptide ABC superfamily ATP binding cassette transporter, binding protein
TraC2	12	93	Peptide ABC superfamily ATP binding cassette transporter, binding protein
OG1RF_12235	13	n/p	S1 family extracellular protease
Pbp1B	14	n/p	Penicillin-binding protein 1B
PrsA	15	118	Peptidyl-prolyl cis-trans isomerase
MreC	19	n/p	Rod shape-determining protein MreC
MetQ	20	n/p	ABC superfamily ATP binding cassette transporter, binding protein
OG1RF_12509	23	78	Pheromone cAD1 lipoprotein
OG1RF_11718	24	220	Hypothetical protein
OG1RF_11061	26	n/p	Phage tail protein
LytR	32	n/p	Response regulator

497

498

499 References

- 500 1. Ellis, T.N. and M.J. Kuehn, *Virulence and immunomodulatory roles of*
501 *bacterial outer membrane vesicles*. *Microbiol Mol Biol Rev*, 2010. **74**(1): p. 81-
502 94.
- 503 2. Gurung, M., et al., *Staphylococcus aureus produces membrane-derived*
504 *vesicles that induce host cell death*. *PLoS One*, 2011. **6**(11): p. e27958.
- 505 3. Rivera, J., et al., *Bacillus anthracis produces membrane-derived vesicles*
506 *containing biologically active toxins*. *Proceedings of the National Academy of*
507 *Sciences*, 2010. **107**(44): p. 19002-19007.
- 508 4. Yonezawa, H., et al., *Analysis of outer membrane vesicle protein involved in*
509 *biofilm formation of Helicobacter pylori*. *Anaerobe*, 2011. **17**(6): p. 388-90.
- 510 5. Grull, M.P., M.E. Mulligan, and A.S. Lang, *Small extracellular particles with*
511 *big potential for horizontal gene transfer: membrane vesicles and gene*
512 *transfer agents*. *FEMS Microbiol Lett*, 2018. **365**(19).
- 513 6. Sabra, W., H. Lunsdorf, and A.P. Zeng, *Alterations in the formation of*
514 *lipopolysaccharide and membrane vesicles on the surface of Pseudomonas*
515 *aeruginosa PAO1 under oxygen stress conditions*. *Microbiology*, 2003. **149**(Pt
516 10): p. 2789-95.
- 517 7. Turnbull, L., et al., *Explosive cell lysis as a mechanism for the biogenesis of*
518 *bacterial membrane vesicles and biofilms*. *Nat Commun*, 2016. **7**.
- 519 8. McBroom, A.J. and M.J. Kuehn, *Release of outer membrane vesicles by*
520 *Gram-negative bacteria is a novel envelope stress response*. *Molecular*
521 *microbiology*, 2007. **63**(2): p. 545-558.
- 522 9. Zlatkov, N., et al., *Eco-evolutionary feedbacks mediated by bacterial*
523 *membrane vesicles*. *FEMS Microbiology Reviews*, 2020.
- 524 10. Lee, E.Y., et al., *Gram-positive bacteria produce membrane vesicles:*
525 *Proteomics-based characterization of Staphylococcus aureus-derived*
526 *membrane vesicles*. *Proteomics*, 2009. **9**(24): p. 5425-5436.
- 527 11. Liao, S., et al., *Streptococcus mutans extracellular DNA is upregulated during*
528 *growth in biofilms, actively released via membrane vesicles, and influenced by*
529 *components of the protein secretion machinery*. *Journal of bacteriology*, 2014.
530 **196**(13): p. 2355-2366.
- 531 12. Biagini, M., et al., *The human pathogen Streptococcus pyogenes releases*
532 *lipoproteins as Lipoprotein-rich Membrane Vesicles*. *Molecular & Cellular*
533 *Proteomics*, 2015.
- 534 13. Wagner, T., et al., *Enterococcus faecium produces membrane vesicles*
535 *containing virulence factors and antimicrobial resistance related proteins*.
536 *Journal of proteomics*, 2018. **187**: p. 28-38.
- 537 14. Lee, J.H., et al., *Transcription factor σ B plays an important role in the*
538 *production of extracellular membrane-derived vesicles in Listeria*
539 *monocytogenes*. *PLoS one*, 2013. **8**(8): p. e73196.

- 540 15. Kuehn, M.J. and N.C. Kesty, *Bacterial outer membrane vesicles and the host-*
541 *pathogen interaction*. Genes Dev, 2005. **19**(22): p. 2645-55.
- 542 16. Rath, P., et al., *Genetic regulation of vesiculogenesis and immunomodulation*
543 *in Mycobacterium tuberculosis*. Proceedings of the National Academy of
544 Sciences, 2013. **110**(49): p. E4790-E4797.
- 545 17. Resch, U., et al., *A Two-Component Regulatory System Impacts Extracellular*
546 *Membrane-Derived Vesicle Production in Group A Streptococcus*. mBio,
547 2016. **7**(6): p. e00207-16.
- 548 18. Vu, J. and J. Carvalho, *Enterococcus: review of its physiology, pathogenesis,*
549 *diseases and the challenges it poses for clinical microbiology*. Frontiers in
550 Biology, 2011. **6**(5): p. 357-366.
- 551 19. Ch'ng, J.-H., et al., *Biofilm-associated infection by enterococci*. Nature
552 Reviews Microbiology, 2019. **17**(2): p. 82-94.
- 553 20. Gilmore, M.S., *The enterococci: pathogenesis, molecular biology, and*
554 *antibiotic resistance*. 2002: Zondervan.
- 555 21. Miller, W.R., et al., *Vancomycin-Resistant Enterococci: Therapeutic*
556 *Challenges in the 21st Century*. Infect Dis Clin North Am, 2016. **30**(2): p. 415-
557 39.
- 558 22. Nielsen, H.V., et al., *The metal ion-dependent adhesion site motif of the*
559 *Enterococcus faecalis EbpA pilin mediates pilus function in catheter-*
560 *associated urinary tract infection*. MBio, 2012. **3**(4): p. e00177-12.
- 561 23. Sjöström, A.E., et al., *Membrane vesicle-mediated release of bacterial RNA*.
562 Scientific reports, 2015. **5**.
- 563 24. Rashid, R., et al., *Comprehensive analysis of phospholipids and glycolipids in*
564 *the opportunistic pathogen Enterococcus faecalis*. PLoS One, 2017. **12**(4): p.
565 e0175886.
- 566 25. Bligh, E.G. and W.J. Dyer, *A rapid method of total lipid extraction and*
567 *purification*. Can J Biochem Physiol, 1959. **37**(8): p. 911-7.
- 568 26. Beveridge, T.J., *Structures of gram-negative cell walls and their derived*
569 *membrane vesicles*. Journal of bacteriology, 1999. **181**(16): p. 4725-4733.
- 570 27. Lee, E.Y., et al., *Proteomics in gram-negative bacterial outer membrane*
571 *vesicles*. Mass spectrometry reviews, 2008. **27**(6): p. 535-555.
- 572 28. Jiang, Y., et al., *Membrane vesicles of Clostridium perfringens type A strains*
573 *induce innate and adaptive immunity*. International Journal of Medical
574 Microbiology, 2014. **304**(3): p. 431-443.
- 575 29. Lopez, D. and G. Koch, *Exploring functional membrane microdomains in*
576 *bacteria: an overview*. Curr Opin Microbiol, 2017. **36**: p. 76-84.
- 577 30. Rashid, R., M. Veleba, and K.A. Kline, *Focal Targeting of the Bacterial*
578 *Envelope by Antimicrobial Peptides*. Front Cell Dev Biol, 2016. **4**: p. 55.
- 579 31. Kandaswamy, K., et al., *Focal targeting by human beta-defensin 2 disrupts*
580 *localized virulence factor assembly sites in Enterococcus faecalis*. Proc Natl
581 Acad Sci U S A, 2013. **110**(50): p. 20230-5.

- 582 32. Tran, T.T., et al., *Daptomycin-Resistant Enterococcus faecalis Diverts the*
583 *Antibiotic Molecule from the Division Septum and Remodels Cell Membrane*
584 *Phospholipids*. mBio, 2013. **4**(4): p. e00281-13.
- 586 33. Elias, J.E. and S.P. Gygi, *Target-decoy search strategy for increased*
587 *confidence in large-scale protein identifications by mass spectrometry*. Nat
588 *Methods*, 2007. **4**(3): p. 207-14.
- 589 34. McBride, S.M., et al., *Genetic diversity among Enterococcus faecalis*. PloS
590 *one*, 2007. **2**(7): p. e582.
- 591 35. Domingues, S. and K.M. Nielsen, *Membrane vesicles and horizontal gene*
592 *transfer in prokaryotes*. Curr Opin Microbiol, 2017. **38**: p. 16-21.
- 593 36. Dorward, D.W., C.F. Garon, and R.C. Judd, *Export and intercellular transfer of*
594 *DNA via membrane blebs of Neisseria gonorrhoeae*. Journal of bacteriology,
595 1989. **171**(5): p. 2499-2505.
- 596 37. Rumbo, C., et al., *Horizontal transfer of the OXA-24 carbapenemase gene via*
597 *outer membrane vesicles: a new mechanism of dissemination of carbapenem*
598 *resistance genes in Acinetobacter baumannii*. Antimicrob Agents Chemother,
599 2011. **55**(7): p. 3084-90.
- 600 38. Jiang, Y., et al., *Membrane vesicles of Clostridium perfringens type A strains*
601 *induce innate and adaptive immunity*. International Journal of Medical
602 *Microbiology*, 2014. **304**(3-4): p. 431-443.
- 603 39. Klieve, A.V., et al., *Naturally Occurring DNA Transfer System Associated with*
604 *Membrane Vesicles in Cellulolytic Ruminococcus spp. of Ruminant Origin*.
605 *Applied and Environmental Microbiology*, 2005. **71**(8): p. 4248-4253.
- 606 40. Prados-Rosales, R., et al., *Mycobacteria release active membrane vesicles*
607 *that modulate immune responses in a TLR2-dependent manner in mice*. The
608 *Journal of clinical investigation*, 2011. **121**(4): p. 1471-1483.
- 609 41. Tien, B.Y.Q., et al., *Enterococcus faecalis Promotes Innate Immune*
610 *Suppression and Polymicrobial Catheter-Associated Urinary Tract Infection*.
611 *Infection and Immunity*, 2017. **85**(12): p. e00378-17.
- 612 42. Zhang, L., et al., *Staphylococcus aureus Bacteriophage Suppresses LPS-*
613 *Induced Inflammation in MAC-T Bovine Mammary Epithelial Cells*. Frontiers in
614 *Microbiology*, 2018. **9**(1614).
- 615 43. Van Belleghem, J.D., et al., *Pro- and anti-inflammatory responses of*
616 *peripheral blood mononuclear cells induced by Staphylococcus aureus and*
617 *Pseudomonas aeruginosa phages*. Scientific reports, 2017. **7**(1): p. 8004-
618 8004.
- 619 44. Sweere, J.M., et al., *Bacteriophage trigger antiviral immunity and prevent*
620 *clearance of bacterial infection*. Science, 2019. **363**(6434).
- 621 45. Pathirana, R.D. and M. Kaparakis-Liaskos, *Bacterial membrane vesicles:*
622 *Biogenesis, immune regulation and pathogenesis*. Cell Microbiol, 2016.
623 **18**(11): p. 1518-1524.

- 624 46. Jeon, J., et al., *Comparative lipidomic profiling of the human commensal*
625 *bacterium Propionibacterium acnes and its extracellular vesicles*. RSC
626 *advances*, 2018. **8**(27): p. 15241-15247.
- 627 47. Mukherjee, S., T.T. Soe, and F.R. Maxfield, *Endocytic sorting of lipid*
628 *analogues differing solely in the chemistry of their hydrophobic tails*. *The*
629 *Journal of cell biology*, 1999. **144**(6): p. 1271-1284.
- 630 48. Cooke, I.R. and M. Deserno, *Coupling between lipid shape and membrane*
631 *curvature*. *Biophysical journal*, 2006. **91**(2): p. 487-495.
- 632 49. Boes, A., et al., *Regulation of the Peptidoglycan Polymerase Activity of*
633 *PBP1b by Antagonist Actions of the Core Divisome Proteins FtsBLQ and*
634 *FtsN*. *mBio*, 2019. **10**(1): p. e01912-18.
- 635 50. Lee, T.K., et al., *Single-molecule imaging reveals modulation of cell wall*
636 *synthesis dynamics in live bacterial cells*. *Nature Communications*, 2016. **7**(1):
637 p. 13170.
- 638 51. Morlot, C., et al., *Growth and division of Streptococcus pneumoniae:*
639 *localization of the high molecular weight penicillin-binding proteins during the*
640 *cell cycle*. *Molecular microbiology*, 2003. **50**(3): p. 845-855.
- 641 52. Kristich, C.J., C.L. Wells, and G.M. Dunny, *A eukaryotic-type Ser/Thr kinase*
642 *in Enterococcus faecalis mediates antimicrobial resistance and intestinal*
643 *persistence*. *Proceedings of the National Academy of Sciences*, 2007. **104**(9):
644 p. 3508-3513.
- 645 53. Labbe, B.D. and C.J. Kristich, *Growth- and Stress-Induced PASTA Kinase*
646 *Phosphorylation in Enterococcus faecalis*. *Journal of Bacteriology*, 2017.
647 **199**(21): p. e00363-17.
- 648 54. Zucchini, L., et al., *PASTA repeats of the protein kinase StkP interconnect cell*
649 *constriction and separation of Streptococcus pneumoniae*. *Nature*
650 *Microbiology*, 2018. **3**(2): p. 197-209.
- 651 55. Beilharz, K., et al., *Control of cell division in Streptococcus*
652 *pneumoniae by the conserved Ser/Thr protein kinase StkP*.
653 *Proceedings of the National Academy of Sciences*, 2012. **109**(15): p. E905-
654 E913.
- 655 56. Nguyen, M.-T., et al., *Lipoproteins in Gram-Positive Bacteria: Abundance,*
656 *Function, Fitness*. *Frontiers in Microbiology*, 2020. **11**(2312).
- 657 57. Xayarath, B., F. Alonzo, III, and N.E. Freitag, *Identification of a Peptide-*
658 *Pheromone that Enhances Listeria monocytogenes Escape from Host Cell*
659 *Vacuoles*. *PLOS Pathogens*, 2015. **11**(3): p. e1004707.
- 660 58. Du, X., et al., *Three novel mammalian toll-like receptors: gene structure,*
661 *expression, and evolution*. *Eur Cytokine Netw*, 2000. **11**(3): p. 362-71.
- 662 59. Dalpke, A., et al., *Activation of toll-like receptor 9 by DNA from different*
663 *bacterial species*. *Infection and immunity*, 2006. **74**(2): p. 940-946.
- 664 60. Giordano, N.P., M.B. Cian, and Z.D. Dalebroux, *Outer Membrane Lipid*
665 *Secretion and the Innate Immune Response to Gram-Negative Bacteria*.
666 *Infection and Immunity*, 2020. **88**(7): p. e00920-19.

667 61. Kandasamy, P., et al., *Structural analogs of pulmonary surfactant*
668 *phosphatidylglycerol inhibit toll-like receptor 2 and 4 signaling*. Journal of lipid
669 research, 2016. **57**(6): p. 993-1005.

670

Figure 1.






Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 1. *E. faecalis* produces MVs ranging from 40-400 nm in size. (A) 22 fractions consisting of 200 μ L each were collected from the top of a 4.4 mL OptiPrep gradient, separated by SDS-PAGE, and silver stained. (B) Selected fractions (# 3, 7, 15, 21 indicated in the boxes in panel A) were negative stained and viewed by TEM. Scale bar is 200 nm. (C) In-situ imaged live *E. faecalis* on the agar pad. Panels of consecutive frames (+0.2 sec) from two distinct area on the pad. Existing vesicle is indicated with a red arrow, the new vesicle - with a yellow arrow. Scale bar 1 μ L.

Figure 2. MVs are enriched in polyunsaturated PG species. Constituent distribution of individual lipid species from whole cell lysate (WCL) or MVs within the analysed lipid classes (A) phosphatidylglycerol (PG), (B) diglucosyl-diacylglycerol (DGDAG), and (C) lysyl-phosphatidylglycerol (Lys-PG). Each stack represents the mean from 6 biological replicates. *, $P \leq 0.05$; **, $P \leq 0.01$; ****, $P \leq 0.0001$; Fisher's LSD test for one-way ANOVA.

Figure 3. MVs possess a unique protein profile with enrichment and abundance of “signature” proteins. The Venn diagram shows the top 15 most abundant and enriched proteins in the MV fraction, by annotation where available or by gene number. Abundance was calculated as the number of unique peptides/total number of peptides. Enrichment was calculated as abundance in MVs/abundance in WCL. The gene description and position within each fraction are listed in **Table 1** in descending order based on the rank of abundance.

Figure 4. Phage tails co-purify with MVs, but phage tail production does not contribute to MV abundance. (A) TEM on assembled phage tails that are present within purified MVs. Scale bar is 100 nm. (B) TEM image of negatively stained *E. faecalis*, where MVs are associated with the cells surface. Scale bar is 100 nm. (C) The concentration of MVs in WT and the $\Delta pp2$ mutant as determined by Nanosight from 3 independent experiments. Statistical analysis was performed by the unpaired t-test. ns: $P > 0.05$.

Figure 5. Plasmid DNA co-purifies with MVs but is not transferred to *E. faecalis* or *E. coli* cells. (A) DNA concentration was measured by Qubit in intact MV samples and in MVs lysed by boiling. Data shown from 3 independent experiments. Statistical analysis was performed by the unpaired t-test using GraphPad. ****, $P < 0.0001$. (B) Agarose gel showing PCR product amplified with plasmid-specific

primers on crude and purified MV fractions of WT and WT pGCP123. The expected plasmid PCR product is 240 bp. **(C)** Agarose gel showing PCR product amplified with plasmid-specific primers on intact and lysed MVs from WT pGCP123, subjected to DNase treatment or treatment with inactivated DNase prior to PCR. DNase treated pGCP123 serves as a control. **(D)** The number of transformants following *E. faecalis* and *E. coli* incubation with MVs extracted from WT or WT pGCP123 determined by CFU enumeration on non-selective BHI or selective media with kanamycin. Statistical analysis was performed by the one-way ANOVA using one-way ANOVA test with Tukey's multiple comparison test. ****, $P < 0.0001$.

Figure 6. MVs but not phage tails activate NF- κ B pathway in macrophages.

RAW-blue cells derived from RAW267.4 macrophages were stimulated with lipopolysaccharide (LPS) at 100 ng/mL (positive control), OptiPrep (OP) (negative control), MV-free concentrated supernatant in OptiPrep from WT and $\Delta pp2$ (WT_{OP} S/N and $\Delta pp2_{OP}$ S/N) (secondary controls), MVs derived from WT and $\Delta pp2$ at 1000 particles/macrophage, and LPS + MVs. Six hours after stimulation, the NF- κ B response was measured by secreted embryonic alkaline phosphatase reporter activity, transcribed from the plasmid under NF- κ B inducible promoter. Statistical analysis was performed by the one-way ANOVA using one-way ANOVA test with Tukey's multiple comparison test. ****, $P < 0.0001$, ** $P < 0.001$, ns: $P > 0.05$ among all of the conditions as compared to OptiPrep negative control.